Axsome Therapeutics. has been granted a patent for a method to treat migraine pain by orally administering a combination of meloxicam and rizatriptan. The method targets individuals with a history of depression, aiming to enhance the bioavailability and pharmacokinetics of the NSAID during acute migraine attacks. GlobalData’s report on Axsome Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Axsome Therapeutics, Antibody-conjugate nanoparticles was a key innovation area identified from patents. Axsome Therapeutics's grant share as of June 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Combination treatment for migraine using meloxicam and rizatriptan
The granted patent US12005118B2 outlines a method for treating migraines in individuals with a history of depression. The treatment involves the oral administration of a combination of meloxicam, ranging from 15 mg to 30 mg, and rizatriptan, with a specified dosage of 8 mg to 13 mg of the rizatriptan free base or its salt equivalent. The claims detail that this combination is effective for patients experiencing moderate to severe migraine pain, including associated symptoms such as photophobia, phonophobia, and nausea. Notably, the method claims that patients may experience a reduction in migraine pain within one hour and up to 24 hours after administration, as well as a decrease in the use of other pain medications by at least 20%.
Further claims specify the formulation of the combination, indicating that it may contain approximately 20 mg of meloxicam in its free acid form or a salt equivalent, alongside rizatriptan. The patent also highlights the potential for rapid absorption of meloxicam, with a Tmax (time to reach maximum concentration) of one to two hours post-administration. Additionally, the claims include specific references to the treatment's efficacy in alleviating symptoms associated with migraines, such as photophobia and nausea, within two hours of taking the combination. The patent emphasizes the therapeutic benefits of this combination for individuals suffering from migraines, particularly those with a history of depression, thereby addressing a significant need in migraine management.
To know more about GlobalData’s detailed insights on Axsome Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
